Sent to Destroy: The Ubiquitin Proteasome System Regulates Cell Signaling and Protein Quality Control in Cardiovascular Development and Disease by Willis, Monte S. et al.
Sent to Destroy: The Ubiquitin Proteasome System Regulates Cell
Signaling and Protein Quality Control in Cardiovascular
Development and Disease
Monte S. Willis1,2, W.H. Davin Townley-Tilson3, Eunice Y. Kang1, Jonathon W.
Homeister1,2, and Cam Patterson1,3,4
1 McAllister Heart Institute, University of North Carolina, Chapel Hill, NC
2 Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC
3 Departments of Cell and Developmental Biology, University of North Carolina, Chapel Hill, NC
4 Departments of Medicine and Pharmacology, University of North Carolina, Chapel Hill, NC
Abstract
The ubiquitin proteasome system (UPS) plays a crucial role in biological processes integral to the
development of the cardiovascular system and cardiovascular diseases. The UPS prototypically
recognizes specific protein substrates and places polyubiquitin chains on them for subsequent
destruction by the proteasome. This system is in place to degrade not only misfolded and damaged
proteins, but is essential also in regulating a host of cell signaling pathways involved in proliferation,
adaptation to stress, regulation of cell size, and cell death. During the development of the
cardiovascular system, the UPS regulates cell signaling by modifying transcription factors, receptors,
and structural proteins. Later, in the event of cardiovascular diseases as diverse as atherosclerosis,
cardiac hypertrophy, and ischemia reperfusion injury, ubiquitin ligases and the proteasome are
implicated in protecting and exacerbating clinical outcomes. However, when misfolded and damaged
proteins are ubiquitinated by the UPS, their destruction by the proteasome is not always possible due
to their aggregated confirmations. Recent studies have discovered how these ubiquitinated misfolded
proteins can be destroyed by alternative “specific” mechanisms. The cytosolic receptors p62, NBR,
and HDAC6 recognize aggregated ubiquitinated proteins and target them for autophagy in the process
of “selective autophagy”. Even the ubiquitination of multiple proteins within whole organelles that
drive the more general macro-autophagy may be due, in part, to similar ubiquitin-driven mechanisms.
In summary, the cross-talk between the UPS and autophagy highlight the pivotal and diverse roles
the UPS plays in maintaining protein quality control and regulating cardiovascular development and
disease.
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A growing number of studies implicate post-translational modifications by the ubiquitin
proteasome system (UPS) in regulating the complex cell signaling processes fundamental to
cardiovascular development and disease. More recently though, our understanding of the role
of the UPS in protein quality control has expanded with new studies delineating its role in the
endoplasmic reticulum and its cross talk with the process of autophagy. In this review, we
present recent evidence that suggests that the UPS plays an essential role not only in
cardiovascular development, but also in the dynamic pathophysiology of cardiovascular
diseases (Table 1).
Overview of the Ubiquitin Proteasome System
The destruction of proteins at the cellular level is a dynamic process regulated primarily by the
ubiquitin proteasome system (UPS). The UPS is a cascade of carefully regulated enzymes
which consist of E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and
E3 (ubiquitin ligase) enzymes (see Figure 1A) which target proteins for destruction by the
proteasome. Each of these enzymes (E1, E2, and E3) plays a unique role in the post-
translational modification of specific proteins. The E1 uses ATP to generate a high energy
thioester bond with ubiquitin between catalytic cysteine residues within E1 and the c-terminal
glycine residue of ubiquitin. This “activated” ubiquitin is then available to be transferred to
one of the ubiquitin conjugating enzymes (E2). There are dozens of these E2 enzymes to which
the charged ubiquitin is added. These E2 enzymes then interact with of one of the hundreds of
ubiquitin ligases (E3) to transfer the activated ubiquitin to the epsilon-amino group of a lysine
residue in the target protein. The ubiquitin on the target protein then serves as an “acceptor”
on which additional ubiquitins can be added. Several cycles of this ubiquitin ligase activity
results in a poly-ubiquitin chain being formed on the target protein.
Ubiquitin is a 76 amino acid moiety with multiple lysines capable of making isopeptide
linkages to form polyubiquitin chains (Figure 1B). This allows a diversity of polubiquitin chain
configurations that can drive different fates for the proteins to which they are attached. The
most commonly identified polyubiquitin linkages occurs on the lysine at amino acid 48
(Lys48). Polyubiquitin chains that link through its Lys48 are called canonical ubiquitin chains
and target the ubiquitinated substrate for destruction. However, there are a total of seven lysine
moieties in ubiquitin which can be used for chain formation (Lys6, Lys11, Lys27, Lys29, Lys
33, Lys48, Lys63)1. Conformationally, polyubiquitin chains formed through Lys63 have been
identified to be more linear than chain made through Lys48 as illustrated in Figure 1B. Lys63
polyubiquitin chains can modify the activity of the target proteins 2 and have been implicated
in DNA repair mechanisms3 and in the regulation of physiologic cardiac hypertrophy2. The
significance of the addition of polyubiquitin chains formed through the noncanonical lysines
(Lys6, Lys11, Lys 27, Lys29, Lys33) has not been completely elucidated. The addition of a
single ubiquitin on a protein, called mono-ubiquitination, regulates DNA repair, nuclear export,
and histone regulation. In the heart, several signaling processes are regulated by
monoubiquitination in the heart, including receptors involved in signaling pathways (EGF)4,
cell-to-cell electrical coupling (connexin 43)5, 6, apoptosis (caspase 3 and caspase 7) 7, and
calcium regulation (via calmodulin)8. The post-translational modification of a protein by poly-
or mono-ubiquitination may determine its fate and regulate its activity. For example,
polyubiquitin chains may target misfolded proteins for degradation while monoubiquitination
may tag these same proteins for delivery to other cellular compartments effectively inhibiting
their activity9. De-ubiquitinating enzymes (DUBs) counteract the ubiquitination process
(Figure 1A). The nearly 100 described DUBs cleave ubiquitin and help recycle ubiquitin
removed at the 26S proteasome as ubiquitinated proteins are degraded 10. Not only can DUBs
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reverse the modification of ubiquitinated proteins, they play a role in the remodeling of
polyubiquitin chains10.
The UPS regulates cell signaling in vascular development
Development of the vascular system is one of the earliest and most pivotal events that occur
during embryogenesis. The development of blood vessels de novo occurs when mesodermally
derived angioblasts differentiate to form primitive blood vessels (vasculogenesis). Sprouting
and bridging of this primary plexus occurs through angiogenesis, where endothelial cell
outlines are covered by smooth muscle cells in the large vessels. Arteriogenesis, the process
of remodeling existing capillaries in response to increased flow demand, is also fundamentally
involved in vascular development. These processes all regulate precursor cells in the
developing embryo as well as in the adult through common signaling pathways such as Notch,
VEGF, and HIF1α among others11, 12. In turn, each of these signaling pathways can be and
are regulated by the UPS.
UPS regulation of Notch signaling
The UPS regulates Notch signaling by its interaction with and regulation of the Notch
antagonist Numb. The ubiquitin ligase LNX can ubiquitinate Numb, preventing internal
sequestration of Notch, resulting in enhanced downstream Notch signaling 13. The ubiquitin
ligase Itch can polyubiquitinate Notch in the absence of a ligand, promoting endocytosis and
inhibition of Notch 14. Furthermore, during vascular development the ubiquitin ligase FBW7/
Sel-10 can target Notch to the proteasome for degradation 15. Adding to the complexity of
UPS-mediated regulation of Notch, is the fact that Notch ligands are also targets of proteasomal
degradation. Two studies have demonstrated that the Mind Bomb (MIB) family of ubiquitin
ligases serves a regulatory role in Notch ligand signaling, with individual family members
temporally restricted in expression to either revascularizing adult tissue (MIB2) or the
developing embryo (MIB1) 16, 17.
UPS regulation of VEGF signaling
Perhaps the most widely studied component of vascular development is VEGF signaling.
VEGF signaling is crucial for angiogenesis, vasculogenesis, cell migration, proliferation, and
cell survival18. Mice lacking VEGF die at ~ E8.5 and have significant impairments in
angiogenesis and blood-island formation 19. On the opposite end of the spectrum, even modest
increases in VEGF disrupt vascular development 20. Improper regulation of VEGF has also
been implicated in the pathophysiology of pulmonary inflammatory disease, cancer
proliferation, diabetic retinopathy, and rheumatoid arthritis. The VEGF-receptor 2 can be
ubiquitinated by Nedd-4, targeting it to the proteasome for degradation21. However, this
Nedd-4 mediated regulation can itself be regulated by its association with Grb10 21. VEGF is
also regulated by oxygen sensing mechanisms; the ubiquitin ligase VHL regulates hypoxia
inducible factor 1 (HIF1) to adapt to low oxygen concentrations.
UPS regulation of smooth muscle cell development
Another major component of vascular development involves the development of vascular
smooth muscle cells (SMCs). The precise coordination of proliferation and differentiation of
SMCs is required for proper vasculature. Recent studies indicate that the ubiquitin ligase CHIP
(C terminus of Hsc70-interacting protein) mediates both SMC differentiation and proliferation
through ubiquitination and proteasomal destruction of specific substrates. CHIP’s targeting of
myocardin, a key co-transcription factor of SRF, decreases in SMC differentiation 22. However,
when CHIP targets FOXO1, a repressor of SMC differentiation, the subsequent FOXO1
repression is ameliorated, thus mitigating apoptosis and enhancing SMC growth 23. Other
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ubiquitin ligases (i.e. Skp2, MDM2) have been described in SMC biology, but their role in
differentiation has yet to be explored 24, 25.
HIF1α as a prototypic transcription factor regulated by the UPS in vascular development
The best characterized ubiquitin ligase that regulates vascular development is hypoxia
inducible factor 1 (HIF1). The HIF1 signaling cascade mediates the necessary adaptations the
vasculature needs to make in the presence of low oxygen concentrations, including the
formation of vessels in both embryos and adults. HIF1 is a dimeric transcription factor
composed of an α andβ subunit. Under normoxic conditions, HIF1α subunits are rapidly
degraded by the UPS. However, in response to decreased oxygen levels, HIF1α becomes
stabilized and transcribes an array of pro-angiogenic factors, such as VEGF, TGF-β3, and
various components of glucose transport and glycolysis, which are generally thought to
overcome vascular insufficiency 26–28. While regulation of HIF1 can occur at the mRNA
level29, it is widely believed its primary regulation is through post-translational modification
and degradation of HIF1α via the UPS.
The von Hippel-Lindau tumor suppressor protein (pVHL) is an essential part of the ubiquitin
ligase complex that negatively regulates HIF1α. During periods of normoxia, prolyl
hydroxylase (PHD) catalyzes the hydroxylation of the HIF1α subunits on conserved proline
residues, converting them into hydroxyproline. This in turn is recognized by the pVHL
ubiquitin ligase complex resulting in HIF1α ubiquitination and subsequent degradation by the
proteasome. A second form of HIF1 inhibition occurs through its interaction with the factor
inhibiting HIF (FIH). FIH binds HIF1 and hydroxylates an asparagine residue on the C-terminal
transactivation domain (C-TAD) of HIF1. This hydroxylation prevents the coactivator p300/
CBP from associating with the C-TAD of HIF1, rendering it transcriptionally inactive. While
apparently redundant, it has recently become clear that FIH and PHD-pVHL modes of HIF1
inhibition operate in segregation as well, depending on the precise oxygen gradient, as
evidenced by mathematical and biological predictions30. Though this canonical view of HIF1
regulation by pVHL and FIH is generally believed to be the predominant modulator in oxygen-
mediated vascular development, other elements exist adding further layers of complexity. For
example, by negatively regulating the activity of PHD enzymes, the ubiquitin ligase Siah2
promotes HIF1 activity at specific O2 concentrations 31. Additionally, the VHL de-ubiquitinase
VDU2 is able to stabilize HIF1α by de-ubiquitinating it, resulting in the enhancement of HIF1
activity32.
Another crucial factor involved in vascular differentiation and development regulated by FIH
is the ankyrin repeat SOCS box protein 4 (ASB4), originally identified as a ubiquitin ligase
that is differentially expressed in vasculature lineages in embryoid bodies 33. ASB4 interacts
directly with FIH and is itself a substrate of FIH-mediated hydroxylation, the results of which
may promote binding to and degradation of substrates of ASB4 33. High levels of ASB4 are
expressed in the embryonic vasculature at times when drastic increases in oxygen tension occur
(E8.5-E9.5) 33. Additionally, in situ mRNA distribution analysis reveals that ASB4 is spatially
compartmentalized to the developing capillary plexi, intersomitic vessels, and placenta 33. As
the vasculature matures and oxygen levels are stabilized, ASB4 is expression is downregulated,
further implicating its role in differentiation. ASB4 makes up a ubiquitin ligase complex with
elongin B/elongin C/cullin/Roc and serves to give the complex its specificity 33.
Overexpression of ASB4 promotes differentiation of vascular precursors into the vascular
lineage in an oxygen-dependent manner, strengthening its proposed role in vascular
development 33.
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Other UPS components linked to signaling in vascular development: FBW7 and Cul7
The substrate recognition protein FBW7 (F-box and WD repeat domain-containing 7) is part
of a conserved Skp1, Cul1, and F-box protein (SCF) type ubiquitin ligase complex. FBW7 is
required for cardiovascular development, as FBW7 null mice die at embryonic day 11 from
impaired cardiac and vascular development 15, 34. Conditional knockouts in hematopoietic
stem cells results in a decrease in all lineages of blood cells (pancytopenia)35 and deletion of
FBW7 in mouse T-cells, disrupting their cell-cycle exit36. Conditional FBW7 knockouts can
also develop leukemia. This is not surprising since FBW7 is implicated in many human cancers,
targeting the destruction of oncogenes such as myc, c-Jun, Notch, and cyclin E35. Cullin is
another component of the SCF ubiquitin ligase complex that has been linked to the developing
vasculature. Arai, et al. identified that the deletion of the Cul1 homologue p185 (Cul7) results
in neonate lethality from respiratory distress37. They further show that embryos exhibit
hemorrhagic vasculature, and abnormal placental endothelial differentiation and vascular
structure. Interestingly, in the same report Cul7 was also shown to form a SCF-like complex
that includes glomulin (aka FAP48 and FAP68), which has been suggested as the loss-of-
function component in familial glomuvenous malformation. This hereditary syndrome is
characterized by abnormalities in vascular morphology and morphogenesis 38.
The role of the UPS in the pathophysiology of atherosclerosis
Recent studies have identified the contribution the UPS makes to the development of
atherosclerosis by regulating vascular inflammation, oxidative stress, apoptosis, and
cholesterol metabolism. These studies, outlined below, provide evidence that implicates the
UPS in many diverse mechanisms that contribute to the pathogenesis of atherosclerosis.
The UPS regulates vascular inflammation and oxidative stress responses
Current dogma states that atherosclerosis is, in large part, an inflammatory disease of the vessel
wall. Several reports provide insight into how the UPS may affect specific components of the
inflammatory response and may therefore modulate the atherosclerotic process. The UPS plays
a role in modifying the function of inflammatory and vascular cells. Regulatory T cell (Treg)
function plays a role in attenuating the inflammatory/immune component of atherogenesis.
Meier, et al. have shown that treatment of Treg cells with oxidized LDL or uremic serum causes
a reduction in proteasomal activity that leads to cell cycle arrest and apoptosis39. They postulate
that the resulting immune dysfunction exacerbates inflammation and atherogenesis in patients,
especially those with end stage renal disease 39. The macrophage, central to the development
of inflammation and atherosclerosis, is dependent in part upon its proteasome activity to
function. Proteasome inhibitors reduce endotoxin-induced gene expression including the Toll-
like receptor 2, and can prevent LPS-induced inflammatory responses 40. Thus, regulation of
the macrophage proteasome activity can modulate the function of these cells and may therefore
alter the atherogenic process. Endothelial cell function is also intimately involved in
atherogenesis, and regulation of endothelial proteasome activity can modulate the
inflammatory phenotype. For example, proteasome inhibition causes the upregulation of
endothelial nitric oxide synthase in endothelial cells and thereby enhances endothelial-
dependent vasorelaxation of rat aortic rings 41. Thus, proteasome function may be necessary
to induce the endothelial cell dysfunction that contributes to atherosclerosis, other vascular
diseases, and systemic diseases characterized in part by vascular dysfunction.
The UPS can also modify the function of various inflammatory mediators. TNFa stimulates
inflammation and immune responses in part through activation of NF-kB, a nuclear
transcription factor that plays an important and central role in the generation of inflammation,
apoptosis and cell proliferation. In carotid artery plaques from patients with various clinical
characteristics, protein ubiquitination and 20S proteasome activity is correlated with the
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presence of TNFa and NF-kB 42–44. Plaques from patients with morning surges in blood
pressure have increased protein ubiquitination and 20S proteasome activity which is associated
with increases in NF-kB, TNFa, inflammatory cell number, markers of oxidative stress, and
matrix metalloproteinase 9, but decreases in collagen content and IkB levels compared to
controls43. Similar findings have been reported in plaques from post-menopausal women not
receiving hormone replacement therapy compared to those who are 44, and in plaques from
diabetics not treated with rosiglitazone compared to those who were treated42. These findings
demonstrate that protein ubiquitination and 20S proteasome activity is associated with
inflammation, oxidative stress, and histologic changes leading to an unstable plaque phenotype.
TNFa also stimulates an increase in the expression of the de-ubiquitinating enzyme
cylindromatosis (CYLD) in endothelial and smooth muscle cells. CYLD inhibits TNFa-
induced NF-kB activation and expression of Cyclin D1 through de-ubiquitination of TNFR-
associated factor 2 (TRAF2) and Bcl-3, respectively. Overexpression of CYLD inhibits cell
viability and neointima formation in a rat model of carotid artery injury 45. A recent study
assessing the role of the UPS in atherosclerosis in rabits investigated how inhibiting the 20S
proteasome by aspirin (ASA) affected atherosclerosis progression. Rabbits were fed a high fat
diet and some were additionally treated with ASA. In ASA-treated rabbits, atherosclerotic
lesions were less apparent and more ubiquitinated proteins were present. Signaling through
NF-κB was inhibited by ASA, as determined by a number of measures, suggesting that the
therapeutic effect of ASA may be due, in part, to the inhibition of the proteasome and
subsequent degradation of IkB46.
Platelet Activating Factor (PAF) is a potent mediator of inflammation thought to be important
in atherogenesis 47. However, its receptor-stimulated activity is characterized by rapid
desensitization due to receptor down-regulation. This down-regulation is due to lysosomal-
and ubiquitin-dependent proteasomal-mediated receptor degradation 48, suggesting that
inhibition of the UPS may exacerbate the effects of PAF on vascular cells and be pro-
atherogenic. Finally, C-reactive protein (CRP), an acute phase protein increased in
inflammation, has been postulated to contribute to atherogenesis 49. A recent study in a strain
of atherosclerosis-prone mice that are low density lipoprotein (LDL) receptor-deficient and
express ApoB100 demonstrated that transgenic expression of human CRP reduces lesion size
and is associated with increased aortic plaque expression of several subunits of the 26S
proteasome. These include genes for the 20S subunit (PSMA7, PSMB7, PSMB9), the 19S cap
unit (PSMC6), and the 11S cap unit (PSME2) 50. These studies provide evidence that the UPS
may modulate the activity and/or function of many of the inflammatory mediators and cell
types that participate in mechanisms of atherogenesis. Given the large number of possible
targets and variation of effects the UPS system has on substrates, predicting the overall role
the UPS has on atherosclerosis will be difficult. This may explain why therapeutic proteasome
inhibition has made atherosclerosis both better and worse, depending on the model42–44, 51–
54.
UPS regulation of vascular cell apoptosis
Certain aspects of lipoprotein metabolism are important in atherosclerosis and may be
modulated by the UPS. It is well accepted that modified forms of low density lipoprotein (LDL)
are risk factors for atherosclerosis. Studies of the effects of aggregated LDL (agLDL) on
macrophages have shown that challenge with agLDL triggers polyubiquitination of
intracellular proteins and ubiquitin-dependent degradation of the apoptosis inducer p53. There
is a concomitant increase in expression of low density lipoprotein-inducible gene (LIG), a
human homologue of the bovine ubiquitin-conjugating (E2) enzyme E2-25K. Inhibiting the
proteasome blocks this anti-apoptotic effect of agLDL, and increases the half-life of p53. Thus,
agLDL may protect macrophages from apoptosis in a LIG- and proteasome-dependent manner
55. Other studies have found a role for the UPS in oxidized LDL (oxLDL)-induced apoptosis
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of vascular cells. OxLDL-induced ubiquitination of cellular proteins induces early activation
but late depression of proteolysis. Proteasome inhibition exacerbates the toxicity of oxLDL,
demonstrating that the UPS may be involved in oxLDL-induced apoptosis 56. OxLDL also
downregulates insulin-like growth factor-1 receptor, leading to smooth muscle cell apoptosis
57. Higashi et al. 58 has demonstrated that this downregulation is dependent on enhanced
Nedd4-dependent receptor ubiquitination, but that degradation of the receptor is independent
of the proteasome pathway. In contrast to earlier studies, these later reports suggest that
ubiquitination and proteasomal activity may enhance apoptosis of certain vascular cell types.
Thus, the role of the UPS in cellular apoptosis and its contribution to atherogenesis may vary
depending on the mechanism of apoptosis and target cell type.
UPS modulation of cholesterol metabolism
Marfella et al. recently summarized the available evidence demonstrating that the UPS may
regulate key processes in the pathogenesis of atherosclerosis 59. They identified that the UPS
regulates: 1) insulin resistance in vascular tissues, 2) hyperglycemia-induced endothelial
activation and dysfunction, and 3) plaque destabilization. Cholesterol metabolism and transport
is central to the development of atherosclerosis, and there is evidence that the UPS may play
a role in these processes. HMGCoA is a key regulatory enzyme of cholesterol synthesis in the
liver, and pharmacologic inhibition of HMGCoA has been very successful in lowering blood
cholesterol concentrations. Studies show that sterol-stimulated turnover of HMGCoA is
mediated by its ubiquitination as well as activity of the 26S proteasome 60, implicating the UPS
in (dys)regulation of cholesterol production for peripheral tissues. The LDL receptor itself has
recently been shown to be regulated by ubiquitin-dependent degradation by the ubiquitin ligase
Idol (inducible degrader of the LDLR), which is transcriptionally regulated by nuclear
receptors to maintain cholesterol homeostasis 61. Overexpressing Idol promotes LDLR
degradation and elevates plasma LDL levels demonstrating its potential anti-atherogenic role
61. Reverse cholesterol transport from peripheral tissues back to the liver is mediated by high
density lipoprotein (HDL), and loading of HDL with cholesterol is mediated by ATP-binding
cassette protein A1 (ABCA1). Work by Azuma, et al. 62 suggests that ABCA1 degradation is
mediated by the COP9 signalosome and is a key controller of ubiquitination. Therefore, the
UPS may modulate atherogenesis, in part, through these several mechanisms involving the
regulation of cholesterol metabolism.
UPS and cardiovascular biology
The UPS regulates a wide array of biological processes in the cardiovascular system (see recent
reviews63–65). For example, the UPS plays a role in the regulation of voltage-gated channels,
including the hERG1 channel linked to familial long QT syndromes. Many of the 200+
mutations in this gene lead to misfolded proteins that are rapidly degraded by the endoplasmic
reticulum-associated degradation (ERAD) pathway (discussed next) 66, 67. The UPS also
regulates a number of signal transduction pathways and transcription factors. The UPS has a
significant role in attenuating MAPK activation 68, signaling through NFAT via calcineurin
69, 70, and in regulating NF-κB signaling71. The UPS also regulates apoptosis directly through
the degradation of caspases (by cIAP, XIAP) and p53 (by MDM2, COP1, Pirh2, ARF-BP1,
CHIP) 63. Additional ubiquitin ligases specifically regulate the pathophysiology of cardiac
diseases, including MuRF1, CHIP, MAFBx/Atrogin-1, and MDM2. The number and diversity
of processes the UPS regulates in the cardiovascular system continues to increase, such that
the role of UPS is now recognized as intimately associated with ER stress, ERAD, and
autophagy in the cardiovascular system.
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ERAD, ER Stress, and the unfolded protein response in the cardiovascular
system
The unfolded protein response (UPR) is a signal transduction system activated in response to
stresses that affect the ability of the ER to properly fold proteins. This system is activated in
response to increased protein misfolding (Figure 2). Several factors are necessary to maintain
efficient protein folding in the ER including the maintenance of the redox state, maintenance
of the glycosylation machinery, as well as chaperones to optimally fold newly formed proteins
in the ER. The ER senses stress by at least 3 transmembrane proteins: 1) the protein kinase R-
like ER kinase (PERK); 2) activating transcription factor-6 (ATF6); and 3) the inositol-
requiring enzyme-1 (IRE-1)72–78. With normal functioning, the ER chaperone GRP78
(glucose-regulated protein 78) bind to the internal ER surfaces of PERK, ATF6, and IRE-1
effectively blocking downstream signaling through these receptors (Figure 2). When normal
protein folding is disrupted, GRP78 accumulates with the misfolded proteins in the ER in an
apparent attempt to refold the proteins (Figure 2) 72–76. Without GRP78 to bind the UPR
receptors in the ER, the three ER receptors mediate downstream signaling in response to the
increase in ER stress. The distal effectors of these three UPR receptors then mediate an arrest
in protein biosynthesis (translation), increased expression in ER responsive genes (including
chaperones, calcium binding proteins, and disulfide isomerases), and effectors of apoptosis
(through CHOP and JNK/Caspase-12) as recently reviewed 79, 80. Through these mechanisms,
the UPR can exert both positive and negative influcences on cell survival.
ER stress signaling pathways in the heart: UPR-mediated protection
The induction of the UPR (or components thereof) protect against ischemic challenge in
cardiomyocytes. Hearts from transgenic mice with cardiac-specific ATF6 overexpression are
protected against ischemia/reperfusion injury, suggesting that ATF6-mediated signaling
upregulates proteins that protect against cell death 81. In cultured cardiomyocytes, increasing
the expression of GRP78 during preconditioning imparts protection 82, 83. Similarly, increasing
the sarcoplasmic reticulum chaperone GRP94 in C2C12 myocytes or H9C2 cardiomyocytes
protects against Ca2+ overload or ischemia-induced cell death determined by propidium iodide
uptake 84. GRP94 overexpression in neonatal cardiomyocytes also results in protection against
simulated ischemia. The UPR in cultured cells can be induced experimentally using the
antibiotic tunicamycin. Tunicamycin-evoked UPR results in an increase in GRP78 in H9C2
cardiomyocytes, and subsequent protection against simulated ischemia/reperfusion 85.
ER stress signaling pathways in the heart: UPR-mediated apoptosis
The UPR also plays a critical role in mediating apoptosis and cell death in response to cardiac
ischemia reperfusion injury. Activation of the UPR can induce apoptosis, while inhibiting it
may protect against ischemia reperfusion-induced cell death. For example, tunicamycin
challenge in cultured cardiomyocytes induces the rapid translocation of deltaPKC and
subsequent cell death, determined by assays for necrosis (LDH release) and apoptosis (caspase
activation, TUNEL staining) 86. However, if deltaPKC activation is inhibited, tunicamycin-
induced cell death is reduced, as are other specific indicators of UPR, such as GRP78 expression
and JNK phosphorylation 86. Similarly, blockade of deltaPKC activation resulting from
ischemia reperfusion injury-induced UPR protects against induced cell death 86. Since the
protein Puma (p53-upregulated modulator of apoptosis) is required for the induction of
cardiomyocyte cell death in ischemia reperfusion injury87, recent studies have investigated its
role in the UPR response. Upregulation of Puma and increased apoptosis are seen in rat and
mouse neonatal cardiomyocytes that have been treated with thapsigargin or tunicamycin to
induce ER stress and the UPR88. Inhibiting Puma significantly protects these cardiomyocytes
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from ER-stress induced apoptosis, suggesting Puma’s critical role in mediating ER-induced
cardiomyocyte death 87.
Temporal regulation of the ER stress response
The ER stress response may be temporally controlled according to recent studies. When
neonatal cardiomyocytes undergo apoptosis in response to simulated ischemia or serum/
glucose/oxygen deprivation, activation of the UPR precedes caspase activation. The initial
response of cardiomyocytes to these stresses is the activation of the UPR, as assessed by
increases in GRP78, XBP1, and eIF2alpha phosphorylation 89. At later time points, the UPR
activation transitions to the activation of CHOP and pro-caspase 12 processing 89. These studies
suggest that UPR effectors initially try to maintain protein quality by increasing the folding
capacity (e.g. increasing the GRP78 chaperone), and later induce apoptosis if they are unable
to overcome the stress. The downstream signaling processes in the cardiomyocyte UPR are
obviously complex given the number of receptors and effectors involved (Figure 2). The
cardiac UPR is also activated by the induction of diabetes by streptozocin 90 and the use of
proteasome inhibitors 91. With the growing prevalence of diabetes and the increased use of
proteasome inhibitors, understanding the ER stress response in the heart may be increasingly
relevant to cardiac health in diseases not primarily of cardiac origin.
The role of ubiquitin ligase N-recognins in cardiac development
Recent studies have identified ubiquitin ligases that recognize structural motifs or degradation
signals (“degrons”) within target proteins present within the substrate structure. A degron is
defined as the minimal part of a protein sufficient for recognition and degradation. There are
three components of the N-degron signal in eukaryotic proteins: 1) a destabilizing N-terminal
residue; 2) its internal lysine residue(s) where the polyubiquitin chain forms; and 3) the
conformational flexibility of areas around these determinants 92–95. Recent studies have
identified that a family of ubiquitin ligases, called N-recognins, mediate the N-end rule pathway
92, 96, 97. Mammalian N-recognins have been identified that recognize N-degrons: UBR1 and
UBR2 (ubiquitin protein ligase E3 component n-recognin 1 and 2) 98, 99. These components
of the N-end rule pathway are essential for proper cardiac development as evideicned by the
wide range of cardiovascular abnormalities seen in UBR1 and UBR2 deficient mice.
The ubiquitin ligases UBR1 and UBR2 are necessary for cardiac development
UBR1 and UBR2 have indistinguishable patterns of binding to N-degrons 98; however, their
in vivo roles do not clearly overlap 100. Mice lacking UBR1 (UBR1 −/−) are viable and fertile,
exhibiting only a mild hypoglycemia, disturbed fatty acid synthase activity and exocrine
pancreatic insufficiency 101, 102. Mice lacking UBR2 (UBR2 −/−) exhibit gender specific
defects: males are viable but infertile while females die as embryos 98. The differences in the
apparent role of UBR1 and UBR2 in development may be due to differential expression
patterns in cell types and tissues, although this has yet to be specifically tested. A better
understanding of the role of UBR1 and UBR2 in development has been achieved by the creation
of UBR1 −/−//UBR2 −/−double null mice 100. These mice die at midgestation with defects in
cardiovascular development. Unlike single UBR1 −/−or UBR2 −/− mice, double null mice had
severe cardiovascular defects characterized by local hemorrhages and a swollen pericardial sac
100. Development of the atria and ventricles is arrested by E10.5 and disorganization of the
myocardial wall and ventricular atrophy is observed 100. Subsequent studies using synthesized
small-molecules that competitively inhibit the recognition of N-recognins have been performed
to determine the specific effects on the heart 103. In both mouse and rat cardiomyocytes, these
studies demonstrate that the N-end rule pathway functions to regulate cardiac proliferation and
hypertrophy, which further supports a role for degrons in cardiac development and the
degradation of important cardiac regulators 103.
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The role of ubiquitin ligases in cardiac disease
Approximately 500 ubiquitin ligases are estimated to exist in the human genome. At least 9
have been described in the heart, with 6 of these (MuRF1, MuRF2, MuRF3, MAFBx/Atrogin-1,
CHIP, MDM2) being mechanistically characterized in cardiac hypertrophy and ischemia
reperfusion injury. In particular, exciting new studies have been published recently implicating
cardiac ubiquitin ligases in cardiac atrophy104, cardiac metabolism 105, and cardiac ischemia
reperfusion injury70. Several recent reviews cover the role of these cardiac ubiquitin ligases in
detail, including the 3 additional ubiquitin ligases (Cbl, E6AP, cIAP) which have distinct
functions described in other model systems 63, 64, 106–108 and so this topic will not be explored
further in this review.
The role of ubiquitin in selective autophagy
Ubiquitination, the proteasome, and autophagy
Misfolding is a constant threat to proteins and results from the presence of oxidative stress,
mutations, and external stresses such as heat shock. To protect against these stresses, the cell
has constitutive and inducible molecular chaperones of the heat shock family to assist in
refolding. Misfolded proteins have exposed hydrophobic residues that, when properly folded,
are not present. Heat shock proteins bind these hydrophobic residues in misfolded proteins and
help to refold them (Figure 3A). A cell’s first option when encountering misfolded proteins is
to refold them. However, if refolding isn’t possible, the protein is slated for degradation by the
proteasome. Evidence demonstrates that ubiquitin ligases interact with heat shock proteins,
illustrating the close relationship within the cell of the processes involved in monitoring protein
quality. These heat shock protein-E3 complexes promote folding and, when this is not possible,
enhance ubiquitination of recognized substrates, targeting misfolded proteins for proteasome
degradation 109.
Misfolded proteins unable to be resolved by chaperone-mediated refolding or proteasome
degradation, form aggregates. Aggregates of misfolded proteins may then polymerize to form
structures microscopically recognized as inclusion bodies (Figure 3B) and aggresomes (Figure
3C) 110, 111. From these structures, bulky, misfolded proteins can be degraded via pathways
that are independent from the proteasome degradation pathway. By shunting protein
degradation to these alternative pathways, the accumulation of ubiquitinated misfolded
proteins can be prevented. The accumulation of protein aggregates is a proximal trigger of
cardiomyocyte autophagy which is the mechanism by which aggresomes can be cleared 112.
Autophagy occurs continuously at low levels in the normal heart. It is regulated by autophagy
(Atg) proteins that make up 2 conjugation pathways that parallel the ubiquitin ligation pathway
described in Figure 1: 1) the Atg12-Atg5 pathway; and 2) the LC3(Atg8)-PE (light chain 3-
phosphatidylethanolamine) pathways (Recently reviewed by Gustafsson et al., 2009113). In
this system, Atg12/Atg5 or Atg8 (LC3) are conjugated to Atg7, Atg10, Atg5, or Atg3 via lysine
residues, forming complexes essential for the recruitment of LC3 and the formation of the
membranes needed to form the autophagosomes (Figure 3D) 114, 115. During cardiac ischemia
or cardiac loading, autophagy increases as a means to adapt to the significant amount of
remodeling that accompanies these processes 113, 116.
Selective autophagy occurs through receptors that recognize ubiquitinated proteins
While the 26S proteasome degrades most intracellular proteins, it is limited in its capacity to
degrade misfolded proteins which become aggregated. Since the proteasome is unable to
degrade these proteins, parallel systems have evolved to help remove proteins that cannot be
degraded by the proteasome. This is done by intracellular receptors which recognize
ubiquitinated protein aggregates, and target these proteins for destruction by the
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autophagosome 117, 118. Autophagy is a general term to describe several processes in which
lysosomes engulf cytosolic proteins for degradation. Recently, a group of loosely associated
receptors have been described that recognize ubiquitin chains covalently attached to proteins
and are capable of delivering ubiquitinated proteins to autophagosomes. Two of these
receptors, p62 and NBR1, target ubiquitinated proteins not cleared by the proteasome for
autophagic clearance. This selective uptake of cellular organelles has previously been
described for mitochondria, aggregations of protein, and bacteria 119. Identifying the receptors
that recognize ubiquitin led to advancements in understanding the underlying mechanisms of
the apparently “specific” (selective) autophagy. There is increasing appreciation that ubiquitin
plays a role in autophagy, and that the uptake of damaged proteins and organelles occurs in a
much more specific way than previously realized.
Selective autophagy: Targeting ubiquitinated proteins for autophagy through p62, NBR1,
HDAC6, and BAG1/BAG3
The multi-functional ubiquitin receptor p62 has recently been identified as part of the
autophagic apparatus 120. p62 contains a zinc-finger domain and ubiquitin-binding UBA
domain in its C-terminal region. The UBA domain is able to bind Lys48-linked and Lys63-
linked ubiquitin chains, with higher affinity for Lys63 (Figure 3) 121–123. The p62-associated
clearance of aggregated proteins by autophagy was first suggested by the discovery of
colocalization of ubiquitin-positive inclusion bodies with p62 124, 125. Further evidence for the
relationship between p62 and LC3 comes from mouse studies 126, 127. Mice with deficiencies
in autophagy (Atg7 −/− mice) display accumulation of p62 in ubiquitin positive inclusion
bodies 127. Mice lacking both Atg7 and p62 (Atg7 −/−//p62−/− mice) have reduced numbers
of protein aggregates 127. The role of p62 in the formation of autophagosomes is further
supported by similar findings in Drosophila 128. Recent studies have also found that p62
regulates the clearance of proteins cleared by the ubiquitin proteasome system. In models where
autophagy is inhibited, p62 accumulation is seen as expected 129. Unexpectedly, however, there
is also decreased clearance of proteins normally removed by the ubiquitin proteasome system,
such as p53, in addition to the accumulation of aggregation prone proteins129.
NBR1 binds ubiquitin by its UBA domain, favoring Lys63-linked poly-ubiquitinated chains
130. The recruitment of ubiquitin-linked cargo to lysosomes is dependent on both p62 and
NBR1. The cross-linking of ubiquitinated misfolded proteins is mediated by NBR1, and like
p62, is necessary for protein aggregation and inclusion body formation following autophagy
inhibition 130. NBR1 associates with itself through its coiled-coiled domain to clear
ubiquitinated misfolded proteins, or it can interact with oligomeric p62 and ubiquitinated mis-
folded proteins 130. In muscle cells, NBR1 interacts directly with p62 and has been implicated
as a part of a signaling complex of the giant protein titin kinase where mechanical stretch-
inducing titin kinase activity is associated with the regulation of the ubiquitin ligase MuRF2
131. An additional role for NBR1 in autophagic degradation of ubiquitinated targets is
illustrated by NBR1’s ability to bind directly to the autophagosome-specific ATG8/LC3/
GABARP in the presence or absence of p62 (Figure 3D) 130.
Histone deacetylase 6 (HDAC6) is another adaptor protein that recognizes ubiquitinated and
misfolded proteins, shuttling them into aggresomes where they are sequestered within the cell
132–134. The aggresomes are then targeted for degradation by the autophagic pathway after
HDAC delivers them via the microtubule organizing centers (MTOC) (Figure 3C). When
aggresomes are experimentally induced with ubiquitinated proteins, they contain HDAC6.
Inhibition of HDAC6 using siRNA reportedly compromises aggresome formation, a process
that can be rescued with HDAC constructs containing the ubiquitin binding region 135. Like
NBR1, HDAC6 binds Lys63-linked ubiquitin chains 133. HDAC6 interacts with dynein motors
necessary for the transport of the aggresome via the microtubules (Figure 3C) 135.
Willis et al. Page 11













Other proteins that do not have ubiquitin binding domains can be associated with ubiquitinated
proteins and autophagosomal markers, including BAG1 and BAG3. The Hsc/Hsp70 co-
chaperone BAG3 has been proposed to mediate autophagic degradation of ubiquitinated
proteins in aging cells 135–137. BAG3 co-localizes with p62-postive aggregated proteins, but
is not itself degraded by autophagy 136. In contrast to BAG3 (found primarily in older cells),
BAG1 mediates the proteasome-dependent degradation of ubiquitinated proteins in
coordination with the CHIP ubiquitin ligase 136, 138. These findings suggest that the ratio of
BAG1/BAG3 changes the mechanism by which aging cells regulate how ubiquitinated proteins
are disposed. The activation of the senescence program, including the increase in the BAG3/
BAG1 ratio, enhances the shuttling of ubiquitinated proteins to autophagy pathways with
advancing age, whereas younger cells with the reverse ratio tend to shuttle ubiquitinated
proteins for proteasomal degradation 136.
Ubiquitination may play a role in selectively degrading whole organelles, such as the
mitochondria139, peroxisomes140, ribosomes141, and bacteria 140. This is most readily seen in
the starvation response. The role of ubiquitin in clearing specific organelles is not fully
understood. Mitochondrial degradation has been reported to be ubiquitin dependent 142, while
autophagy of the peroxisomes is partially dependent on p62 and associated with mono-
ubiquitinated proteins 143. There is much work to be done to understand how complex
organelles are targeted for selective autophagy through ubiquitination and recognition by
adaptor proteins such as p62 and NBR1.
Conclusion
A picture of the UPS as a simple isolated system no longer adequately describes the myriad of
functions it has in the cardiovascular system. The UPS plays a fundamental role in the
development of the vascular system through its regulation of key signaling pathways including
Notch, VEGF, and HIF1. In the mature vasculature, the UPS regulates inflammation, oxidative
stress, and apoptosis in addition to cholesterol metabolism in ways that may affect the
development and severity of atherosclerosis. In the stressed heart, the UPS maintains protein
quality control of nascent proteins in the endoplasmic reticulum by the unfolded protein
response (including signaling through PERK, ATF6, IRE-1) and ER-associated degradation
of misfolded proteins. Despite increasing appreciation of the UPS in regulating a myriad of
biological processes, some of the newest and most fascinating findings implicate autophagy
(“selective autophagy”) as an alternative to the proteasome to get rid of unfolded, damaged,
and aggregated proteins. The cytosolic receptors p62, NBR, and HDAC6 play a fundamental
role in targeting damaged proteins to this extra-proteasomal “selective autophagy” form of
destruction. This emphasizes the fundamental role of the UPS in maintaining protein quality
by the selective destruction of worn and damaged proteins. While our appreciation of the UPS
in maintaining protein quality control continues to grow, so does our realization of the
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Non-standard Abbreviations and Acronyms
agLDL aggregated low density lipoprotein
ASB4 ankyrin repeat and SOCS box-containing 4
ASA aspirin
ATF6 activating transcription factor 6
CHIP c-terminus of Hsp70-interacting protein (CHIP)
CHOP cytosine-cytosine-adenine-adenine-thymine enhancer-binding protein (C/
EBP) homologous protein
COP1 constitutive photomorphic 1 protein
CRP c-reactive protein
C-TAD C-terminal transactivation domain




ERAD endoplasmic reticulum-associated death
FIH factor inhibiting HIF
GRP78 glucose-regulated protein 78
HDL high density lipoprotein
HIF1 hypoxia inducible factor 1
HMGCoA 3-hydroxy-3-methylglutaryl-Coenzyme A synthase
I/R ischemia reperfusion
JNK c-Jun NH2-terminal kinase
c-Jun jun oncogene
LDL low density lipoprotein
LNX ligand of numb-protein X 1
LPS lipopolysaccharide
MAFBx muscle atrophy F-box
MDM2 murine double minute 2
MIB1, 2 mind bomb1/2
MTOC Microtubule organizing centers
MuRF1, 2 Muscle ring finger-1, -2
NF-KB nuclear factor kappa light chain enhancer of activated B cells
oxLDL oxidized low density lipoprotein
PAF platelet activating factor
PERK protein kinase R-like ER kinase
PHD prolyl hydroxylase
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Pirh2 p53-indiced protein with a RING-H2 domain
PKC protein kinase C
SCF Skp1Cul1-F-box-protein
SRF serum response factor
TGF-β transforming growth factor beta
TNF-α tumor necrosis factors-alpha
TRAF2 TNF receptor-associated factor 2
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end labeling
UPR unfolded protein response
UBR1,2 ubiquitin protein ligase E3 component n-recognin 1,2
UPS ubiquitin proteasome system
VEGF vascular endothelial growth factor
pVHL von-Hippel Lindau tumor suppressor
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Figure 1. The ubiquitin proteasome system at a glance
The ubiquitin proteasome is a system of enzymes that places ubiquitin (chains) on specific
protein substrates to target them for degradation, change their localization, and/or enhance their
activity. (A) Free monoubiquitin is activated by the E1 enzyme in an ATP-dependent manner
and transferred to the E2 enzyme. The specificity of the system is in the E3 (ubiquitin ligase)
that mediates the transfer of one or more ubiquitin moieties sequentially to form ubiquitin
chains on the substrate. The canonical lysine chains linked by their lysine48 (Lys48) are
recognized by the 26S proteasome which degrades the protein into constituent peptides and
free ubiquitin. (B) The role of noncanonical polyubiquitination (i.e. Lys63-linked ubiquitin
chains) is increasingly being described in the cardiovascular system as a way to regulate protein
(i.e. transcription factors) activity. A total of seven lysine moieties exist in ubiquitin which can
be used for chain formation (Lys6, Lys11, Lys27, Lys29, Lys 33, Lys48, Lys63). A number
of studies discussed in this review reveal a role for more linear Lys63 chains, in addition to
canonical Lys48 linkages in the cardiovascular system. However, the significance of Lys6,
Lys11, Lys 27, Lys29, Lys33 and branching/complex ubiquitin chains has not been elucidated
in general.
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Figure 2. Endoplasmic reticulum stress and the unfolded protein response
In response to stress, proteins synthesized in the rough endoplasmic reticulum are refolded by
resident molecular chaperones GP78 (glucose-regulated protein-78). Upon refolding, GRP78
looses its association with the luminal domains of the PKR-like ER kinase (PERK), activating
transcription factor-6 (ATF6), and inositol-required enzyme-1 (IRE-1). This leads to PERK,
ATF6, and IRE-1 activation and downstream activation of ER stress response genes which
help stabilize the misfolding of proteins, including ER-targeted chaperones. If the unfolded
proteins are not adequately removed after the activation of the UPR, signaling pathways for
apoptosis can be activated. Adapted from: Glembotski et al., 200780 and Glembotski et al,.
200879.
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Figure 3. Selective Autophagy through recognition of misfolded and ubiquitinated proteins through
NRB1 and p62
(A) Stress-induced misfolding of proteins is a constant threat to the well-being of the cell.
Chaperones continually refold proteins by recognizing the hydrophobic regions of the protein
exposed during stress. Heat shock protein-ubiquitin ligase complexes promote folding, but if
this is not possible they enhance the ubiquitination of recognized substances effectively
targeting proteins for either proteasome degradation (see Figure 1) or by selective autophagy.
(B) Misfolded ubiquitinated proteins can polymerize to form inclusion bodies and (C)
aggresomes which form from the transport of aggregated ubiquitinated proteins that are
transported via dynein on microtubule tracks. (D) “Selective autophagy” is the catabolism of
macromolecule and organelles based on the recognition of ubiquitination chains on proteins
which plays an important role in maintaining protein quality control in the cell. MTOC,
Microtubule organizing centers. Adapted from: Kirkin, et al., 2009130 and Larmark et al., 2009
144.
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Table 1
Proteins involved in the UPS regulation of cardiovascular development and pathophysiology of cardiovascular
diseases
Proteins: Vascular Development Function Role
1. Numb Notch antagonist Ubiquitinated by LNX,
preventing internal
sequestration of Notch
2. Itch Ubiquitin ligase Polyubiquitinates Notch












5. Nedd-4 Ubiquitin ligase Targets VEGF-receptor 2
for proteasomal
degradation
6. VHL (von Hippel-Lindau) Ubiquitin ligase Regulates hypoxia
inducible factor 1 (HIF1)
to adapt to low oxygen
concentrations
7. CHIP (C terminus of Hsc70-
interacting protein)








9. FIH (Factor inhibiting HIF) Hydroxylation factor Binds HIF1 to make it
transcriptionally inactive
10. Siah2 Ubiquitin ligase Promotes HIF1 activity at
specific oxygen
concentrations
11. VDU2 VHL de-ubiquitinase Stabilizes HIF1 by
deubiquitination
12. ASB4 (Ankyrin repeat SOCS box
protein 4)





13. FBW7, Cul 7 Substrate recognition protein/SCF (Skp1,






e.g. myc, c-Jun, Notch,
cyclin E)




Proteins: Atherosclerosis Function Role
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Proteins: Vascular Development Function Role







2. TNFa, NF-kB Inflammatory mediator/transcription factor Correlated with protein
ubiquitination and 20S
proteasome activity
3. CYLD Deubiquitinating enzyme Inhibits TNFa-induced
NF-kB activation and
expression of Cyclin D1
through deubiquitination
of TNFR-associated
factor 2 (TRAF2) and
Bcl-3





5. CRP Acute phase protein Transgenic expression of
human CRP reduced
atherosclerotic lesion size














8. Idol Ubiquitin ligase Regulates LDL receptor
9. COP9 signalosome Mediates ABCA1 (ATP-
binding cassette protein
A1) degradation
Proteins: Cardiovascular Biology Function Role
1. cIAP, XIAP Degrade caspases Regulation of apoptosis
2. MDM2, COP1, Pirh2, ARF-BP1,
CHIP
Degrade p53 Regulation of apoptosis
3. MuRF1, CHIP, MAFBx/
Atrogin-1, MDM2
Ubiquitin ligases Pathophysiology of
various cardiac diseases
Proteins: ERAD, ER Stress,
Unfolded Protein Response (UPR)
Function Role
1. PERK, ATF6, IRE-1 ER transmembrane proteins Mechanisms by which ER
senses stress (Unfolded
Protein Response)
2. GRP78 ER chaperone In normal times, binds to
internal surfaces of
PERK, ATF6, IRE-1 and
blocks downstream
signaling
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Proteins: Vascular Development Function Role
4. Puma (p53-upregulated modulator
of apoptosis)
Modulates apoptosis Upregulated during
induced ER stress and
UPR
Proteins: Cardiac Development Function Role
1. N-recognins: UBR1, UBR2 Ubiquitin ligases Mediate the N-end rule
pathway by recognizing
N-degrons
Proteins: Cardiac Disease Function Role






Proteins: Selective Autophagy Function Role






2. Atg12-Atg5; LC3(Atg8)-PE Autophagy pathways Conjugate to Atg proteins
forming complexes
essential for recruitment
of LC3 and formation of
autophagosome
membranes
3. p62 Intracellular receptor, adaptor protein Recognizes ubiquitin
chains on targeted




4. NBR1 Intracellular receptor, adaptor protein Mediates cross-linking of
ubiquitinated proteins;
interacts w/p62 to clear
misfolded proteins
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